Introduction. To provide an overview of the urological management of spinal cord injured patients based on an economic analysis. Materials and methods. A literature search from January 1994 to December 2014 was performed using Medline and Embase database using the following keywords: cost-effectiveness; cost-benefit; cost-utility; spinal cord injury; neurogenic bladder; intermittent catheterization; antimuscarinics; botulinum toxin; sacral neuromodulation; tibial nerve; Brindley; sphincterotomy. The tool used for comparison was the QALY ("quality adjusted life years"); an indicator between 0 and 1 allowing the comparison between two medical treatments using cost per QALY. Results. - Solifenacin (5 to 10 mg) is the most cost-effective treatment with an incremental cost-effectiveness ratio (ICER) of 19,893 (sic)/QALY compared to trospium 40 mg, of 16,657/QALY compared to trospium 60 mg, of 12,309 (sic)/QALY compared to oxybutinin. Botulinum toxin A is also cost-effective with an ICER of 24,720 $/QALY compared to best supportive cares for anticholinergic-refractory neurogenic detrusor overactivity. Conclusion. Solifenacin and botulinum toxin A appears to be the most cost-effective treatments for spinal injured urological cares. There is a pressing need to both increase and improve data collection and research on spinal cord injury. (C) 2016 Elsevier Masson SAS. All rights reserved.